Dr. Andrew L. Pecora
Claim this profileHackensack University Medical Center
Studies Skin Cancer
Studies Melanoma
11 reported clinical trials
14 drugs studied
Area of expertise
1Skin Cancer
Stage III
Stage IV
Stage I
2Melanoma
Stage IV
Stage III
BRAF positive
Affiliated Hospitals
Clinical Trials Andrew L. Pecora is currently running
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
Biomarker-Guided Immunotherapy Discontinuation
for Melanoma
This trial uses drugs that boost the immune system to fight advanced melanoma that can't be surgically removed. It aims to see if doctors can safely shorten the treatment period by using imaging tests to guide decisions. Pembrolizumab and ipilimumab are immunotherapy drugs used to treat advanced melanoma, with pembrolizumab approved for younger patients and ipilimumab showing positive results in previous studies.
Recruiting1 award Phase 222 criteria
More about Andrew L. Pecora
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Andrew L. Pecora has experience with
- Nivolumab
- Pembrolizumab
- Cemiplimab
- Ipilimumab
- RP1
- Relatlimab
Breakdown of trials Andrew L. Pecora has run
Skin Cancer
Melanoma
Cutaneous Melanoma
Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andrew L. Pecora specialize in?
Andrew L. Pecora focuses on Skin Cancer and Melanoma. In particular, much of their work with Skin Cancer has involved Stage III patients, or patients who are Stage IV.
Is Andrew L. Pecora currently recruiting for clinical trials?
Yes, Andrew L. Pecora is currently recruiting for 2 clinical trials in Hackensack New Jersey. If you're interested in participating, you should apply.
Are there any treatments that Andrew L. Pecora has studied deeply?
Yes, Andrew L. Pecora has studied treatments such as Nivolumab, Pembrolizumab, Cemiplimab.
What is the best way to schedule an appointment with Andrew L. Pecora?
Apply for one of the trials that Andrew L. Pecora is conducting.
What is the office address of Andrew L. Pecora?
The office of Andrew L. Pecora is located at: Hackensack University Medical Center, Hackensack, New Jersey 07601 United States. This is the address for their practice at the Hackensack University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.